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Abstract: Very high IgM levels represent the hallmark of hyper IgM (HIGM) syndromes, a group of
primary immunodeficiencies (PIDs) characterized by susceptibility to infections and malignancies.
Other PIDs not fulfilling the diagnostic criteria for HIGM syndromes can also be characterized by
high IgM levels and susceptibility to malignancies. The aim of this study is to characterize clinical
phenotype, immune impairment, and pathogenic mechanism in six patients with very high IgM levels
in whom classical HIGM syndromes were ruled out. The immunological analysis included extended
B-cell immunophenotyping, evaluation of class switch recombination and somatic hypermutation,
and next generation sequencing (NGS). Recurrent or severe infections and chronic lung changes at
the diagnosis were reported in five out of six and two out of six patients, respectively. Five out of
six patients showed signs of lymphoproliferation and four patients developed malignancies. Four
patients showed impaired B-cell homeostasis. Class switch recombination was functional in vivo in
all patients. NGS revealed, in one case, a pathogenic mutation in PIK3R1. In a second case, the ITPKB
gene, implicated in B- and T-cell development, survival, and activity was identified as a potential
candidate gene. Independent of the genetic basis, very high IgM levels represent a risk factor for the
development of recurrent infections leading to chronic lung changes, lymphoproliferation, and high
risk of malignancies.
Keywords: hyper IgM syndrome; lymphoproliferative disorders; class switch recombination; somatic
hypermutation; DNA repair
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1. Introduction
High IgM levels are found in rare immunological disorders, such as hyper IgM (HIGM) syndromes,
but also in autoimmune or acquired infectious diseases [1–3]. Elevated monoclonal IgM levels are
also found in B-cell lymphoproliferative disorders (LPD) [4,5]. HIGM syndromes are characterized by
normal or increased IgM levels and absent or strongly reduced levels of the other immunoglobulin
isotypes due to impaired class switch recombination (CSR), which is sometimes associated with
abnormal somatic hypermutation (SHM). Both processes require the integrity of cell DNA repair
machinery, although with different repair mechanisms. Within the genetic disorders, so far, six genes
have been implicated, coding for molecules involved in CD40 and CD40 ligand signaling (CD40 and
CD40L), or in cytosine and cytidine deaminase process (AID) [6–8]. Traditionally, HIGM syndromes
are classified in Online Mendelian Inheritance of Man (OMIM) in five groups. HIGM type 1 (OMIM #
308230) is an X-linked (XL) disorder due to CD40L deficiency, accounting for about 70% of the forms
with known genetic basis [9,10]. HIGM type 2 (OMIM # 605258) which is due to mutations in AID gene,
type 3 (OMIM # 606843) which is caused by CD40 defects, and type 5 (OMIM # 608106) which is caused
by mutations in the uracil DNA glycosylase (UNG) are inherited in an autosomal recessive manner.
HIGM type 4 (OMIM # 608184) is a condition with an undefined genetic cause, phenotypically similar
to type 2 [3]. An autosomal-dominant form due to mutations in the C-terminal region of AID has
been described in a few patients [11]. The prevalence of these conditions varies in different ethnicities.
Globally, HIGM constitute 0.3% to 2.9% of all PIDs [12]. The estimated frequency of CD40L deficiency is
2:1,000,000 in males [13]. Autosomal recessive forms are very rare. AID deficiency is estimated to affect
less than 1:1,000,000 individuals [14]. CD40 deficiency is more common than AID deficiency, however,
the real incidence cannot be calculated since the majority of the patients have not been described [10,12].
Other HIGM syndromes are caused by mutations, in post-meiotic segregation 2 (PMS2) and INO80
genes [15–17]. CD40L deficiency represents the most common genetic cause of HIGM syndrome.
Clinical phenotype, pathogenesis, and prognosis related to the treatment of this specific form are
well characterized. Elevated IgM levels were also reported in other well-defined immunodeficiencies,
such as nuclear factor κB (NF-κB) essential modulator (NEMO), recombination-activating gene (RAG)
2, lipopolysaccharide-responsive beige-like anchor (LRBA), ataxia telangiectasia mutated (ATM),
ARTEMIS, and dedicator of cytokinesis (DOCK) 2 deficiency [3,18–23]. Most of these conditions are
characterized by increased susceptibility to malignancies and infections. Recently, novel genetic defects
responsible for primary immunodeficiencies (PIDs) with HIGM have been characterized, thanks to
the introduction of next generation sequencing (NGS) technologies in clinical settings. However, the
genetic origin remains undefined in about 30% of the cases [1]. Clinical manifestations are variable
and peculiar clinical features which are related to specific genetic alterations. However, independent
of the genetic alteration, the overall clinical phenotype of HIGM is usually characterized by increased
susceptibility to recurrent bacterial and opportunistic infections associated with autoimmunity and
cancer susceptibility. The aim of this study is to characterize clinical phenotype, immune impairment,
and functional phenotype in six patients with very high IgM levels, in which classical HIGM syndromes
were ruled out. In particular, we focus on differences and commonalities with XL-HIGM and other
well defined PIDs presenting with high IgM levels that help to predict the prognosis and improve the
management of patients with less characterized forms. Moreover, we also try to shed light on the
pathogenic mechanisms leading to HIGM in these patients.
2. Experimental Section
2.1. Patients
Six patients (four female) from unrelated non-consanguineous families with high IgM levels (range
416–1060 mg/dL) were enrolled in the study, after signed informed consent. CD40L alterations were
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ruled out through direct Sanger sequencing or flow cytometry in all patients. Normal cytofluorimetric
expression was considered sufficient to rule out a CD40L genetic defect, especially in female subjects.
Direct Sanger sequencing also ruled out alterations of the following genes in selected cases, during
the followup: CD40 (Patient 5 (P5) and Patient 6 (P6)), AICDA (Patient 1 (P1) and Patient 4 (P4) to
P6), UNG (P1, P5 and P6), NEMO (P1), TNFRSF13B (P1), and ATM (P1). The study was carried out
in accordance with the Declaration of Helsinki and approved by the institutional Ethical committee
“Carlo Romano” of Federico II University (project identification codes 25/16 and 162/16).
2.2. B-Cell Immunophenotyping and CD40-CD40L Expression
Whole blood anticoagulated with EDTA was used for multicolor flow cytometry
immunophenotyping and processed within 24 h. Cells were exposed to directly conjugated mouse
anti-human monoclonal antibodies (mAb) using the following fluorochrome conjugated antibodies:
anti-CD45 peridinin-chlorophyll (PerCP) or anti-CD45 horizonV500 (HV500), anti-IgD phycoerythrin
(PE), anti-IgM allophycocyanin (APC), and anti-IgG phycoerythrin (PE) all from BD Biosciences
(Becton Dickinson, San Jose, CA, USA); anti-CD19 allophycocyanin (APC) and anti-CD27 FITC all from
Invitrogen (Invitrogen, Carlsbad, CA) and Caltag (Caltag Medsystems, Buckingham, UK). The cells
were incubated with directly labelled antibody at 4 ◦ C in the dark for 30 min, washed and resuspended
in 4 mL of NH4Cl, and then washed in PBS. Flow cytometric analysis was performed on a BD FACS
Canto II flow cytometer (Becton Dickinson, San Jose, CA, USA) and the analysis was performed using
BD FACSDiva software. Lymphocytes were identified by gating on viable CD45+ cells or on FSC and
SSC and B-lymphocytes were gated on CD19+ cells. After 48 h incubation with PMA and ionomycin,
CD40L and CD40 staining was performed through directly conjugated mouse anti-human mAb.
2.3. Study of CSR and SHM In Vitro
Peripheral blood mononuclear cells (PBMCs) were cultured in the presence of 500 ng/mL of
soluble CD40-L and 100 U/mL of rIL-4. Proliferation was assessed by measuring [3H] thymidine
uptake. IgE production was evaluated in supernatants by ELISA on day 12 [24]. SHM generation
in the VH3-23 region of IgM on purified CD19+CD27+ B cells was performed in two patients, as
previously described [8]. VH3-23 region was chosen since V3-23 Ig V gene is expressed in 4% to 10%
of B cells [25]. PBMCs were isolated by flow cytometry using FITC-anti-CD19 and PE-anti-CD27
mAb (Invitrogen, Carlsbad, CA, USA). RNA was purified with Trizol reagent and cDNA was
obtained by reverse transcription with an oligo dT primer. PCR was carried out with Pfu polymerase
(PfuTurbo, Stratagene) (Sigma-Aldrich, St. Louis, MO, USA) using primers for the VH3-23 leader exon
(50 -GGCTGAGCTGGCTTTTTCTTGTGG-30 ) and Cµ region (50 -TCACAGGAGACGAGGGGGAA-30 )
(35 cycles at 94-C for 45 s, 60-C for 1.5 min, and 72-C for 2 min). After amplification by high fidelity
Pfu, addition of 30 A-overhangs post amplification was performed by adding Taq polymerase to the
PCR reaction, and incubating the mix at 72 ◦ C for 10 min before proceeding to TA-cloning, following
manufacture’s recommendation (Invitrogen, Carlsbad, CA, USA). VH3-23 positive colonies were
sequenced with dRhodamine dye terminator cycle sequencing kit (Applied Biosystems prism, Foster
City, CA, USA) and analyzed with Applied Biosystems prism 310 genetic analyzer. Frequency of
mutations, expressed as a percentage of mutated nucleotides and all nucleotides, was evaluated for
each clone on 300 nucleotides of the VH3-23 region including CDR1 and CDR2 domains. Polyclonality
was established based on the diversity of the CDR3 of B cells bearing IgM.
2.4. Whole Exome and Sanger Sequencing
Whole exome sequencing (WES) was performed in 5 cases (P6 died before). Since mutations in
PIK3CD or PIK3R1 genes have been recently reported as responsible for novel PIDs characterized by
elevated IgM, normal/low IgG levels, lymphopenia, respiratory infections, lymph node enlargement,
and elevated risk of lymphomas [26–30], these genes were analyzed by direct sequencing. Variants
in causative or potential candidate genes identified through WES were confirmed through Sanger
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sequencing. Genomic DNA was isolated from peripheral blood lymphocytes using QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany). Samples were sequenced to at least 2.5 GB on Illumina
MiSeq with TruSeq MiSeq V3 reagents, yielding paired 250 nucleotide reads. Samples for exome
sequencing were prepared using TruSeq HT library preparation kit (Illumina; San Diego, CA, USA) and,
subsequently, exome enrichment was performed through xGen Exome Research Panel V1.0 (Integrated
DNA Technologies, Coralville, IA, USA) according to the manufacturer’s protocols. Bioinformatic
analysis was carried out, as previously described [31,32].
2.5. Real-Time qRT-PCR of ITPKB Gene
RNA from Patient 3 (P3) and controls’ PBMCs was extracted using Trizol reagent (Invitrogen,
Carlsbad, CA), and Phase-lock gel columns (Eppendorf, Amburgo, Germany) according to
manufacturer’s instructions. RNA was reverse transcribed by Transcriptor First Strand cDNA Synthesis
Kit (Roche Applied System, Mannheim, Germany). qPCR reactions were performed in duplicate.
Amplification of cDNAs was performed using SYBR Green and analyzed with Light Cycler480 (Roche
Applied Systems, Mannheim, Germany). Cycling conditions comprised an initial denaturation at 94
◦ C for 5 min, a phase of annealing/extension specific for each gene. A dissociation procedure was
performed to generate a melting curve for confirmation of amplification specificity. Primer sequences
for ITPKB were the following: Primer A forward, 50 -GCACTGGTCTCCCTTCGTC-30 ; reverse,
50 -CCAGGTAGGTCCTGATTCCC-30 ; Primer B forward, 50 -GGACACGCAGGGAGTTTCAAG-30 ;
reverse, 50 -TCGTCCATCTGGTTGTAGCG-30 . The primer sequences for Actin were the following:
forward 50 -GATCAAGATCATTGCTCCTCCTG-30 and reverse, 50 -AGGGTGTAAAACGCAGCTCA-30 .
Results are expressed as mean + standard error (SE) of 3 repeated experiments and each gene expression
was normalized to β-actin as the housekeeping gene. The relative transcript abundance was represented
as -DCt = (Ct gene - Ct reference) and the relative changes in gene expression was analyzed using the
2-DDCt method. Data presented as the means ± SD were analyzed with a Student’s t test analysis. P
values <0.01 were considered significant.
3. Results
3.1. Clinical and Immunological Data of HIGM-Like Patients
As shown in Table 1, five out of six patients studied suffered from recurrent bacterial and viral
infections, in particular, of the upper and lower respiratory tract, causing in P1 a significant lung
damage characterized by bronchiectasis and atelectasis. Atelectasis were also found in P4, whereas
interstitial lung disease was documented in Patient 2 (P2). P1 and P2 also experienced complicated
viral infections, including measles complicated by pneumonia (P1) and chickenpox with severe ocular
involvement (P2). Quantitative PCR for EBV, CMV, HCV-RNA, and HBV-DNA, was negative in
patients with hypogammaglobulinemia who underwent intravenus immunoglobulin replacement
therapy (IVIG) (P1, P4–P6). Involvement of the reticulo-endothelial system with lymphadenopathy,
liver and spleen enlargement was documented in five patients. Three patients had autoimmunity or
signs of chronic inflammation, i.e., alopecia (P4), autoimmune myofascitis and recurrent fever (P1,
P2). Other clinical features included urticarial-like lesions or other recurrent skin lesions in four cases,
growth retardation and delayed puberty in two cases, mood and behavioral disorders in two cases,
and Arnold–Chiari malformation in one patient.
In four cases, IgG levels were 2 SD below the mean value of age-matched controls, requiring IGIV,
as shown in Table 2; IgA isotypes were also below reference values in P1, P5, and P6.
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Table 1. Clinical features of the hyper IgM (HIGM)-like patients.
P1

P2

P3

P4

P5

P6†

16
F

49
F

45
M

8
M

15
F

15
F

+
−
+*

+
−
+ **

−
−
−

+
−
−

+
−
−

+
−
−

+
+
−
+
−
−
−

−
−
+
−
−
+
+

−
−
−
+/−
−
−
−

−
+
−
+
+
−
−

−
−
−
+
−
−
−

−
−
−
++
−
−
−

+

+

−

−

−

−

+

−

+

+

−

−

+

+

+

+

−

NHLymphoma

MALTLymphoma

−

−

HodgkinLymphoma

−
Diffuse large
B-cell
Lymphoma

Behavioral
disorder

Growth and
pubertal delay;
bone defects;
Arnold Chiari
syndrome

Age (y)
Sex
Clinical features
Infections
Bacterial
Opportunistic
Viral
Lung disease
Bronchiectasis
Atelectasis
Interstitial lung disease
Lymphadenopathy
Autoimmunity
Inflammatory disease
Recurrent fever
Musculoskeletal
involvement
Liver and/or spleen
enlargement
Cutaneous manifestations
Cancer

Mood
disorder

Other

Growth and
pubertal
delay

NH, non-Hodgkin; MALT, mucosa-associated lymphoid tissue; * P1 experienced a measles complicated by
pneumonia; ** P2 experienced a chickenpox with severe ocular involvement; † patient died.

Table 2. Immunological and molecular findings of HIGM-like patients.
P1
Age (y)

10
Before
LPD

P2
16
After
LPD

P3

34
Before LPD

49
After
LPD

45

P4

P5

P6†

8

15
Before
LPD

15
Before
LPD

565↓
(IVIG)
5↓
443↑

140↓
(IVIG)
5↓
596↑

Immunological features
IgG, mg/dL
IgA, mg/dL
IgM, mg/dL
Lymphocyte absolute
counts/mL
T-cell subsets
CD3+ (% of lympho)
(absolute value)
CD4+
(% of lympho)
CD8+
(% of lympho)
CD56+
(% of lympho)
B-cell subsets
CD19+
(% of lympho)
CD19+CD27+IgM+
(IgM memory, % of CD19+)
CD19+CD27+IgM(switched memory, % of
CD19+)
Genetic alteration
Inheritance

442↓
(IVIG)
19↓
753↑

660

858

788

1500

8.3↓
416↑

282
911↑

332
1060↑

227
516↑

294↓
(IVIG)
33
800↑

7860

6950

NK

3.300

1400

3090

2100

2260

67
(5266)
23
(1807)
40
(3144)
2.7
(212)

72
(5004)
31
(2154)
31
(2154)
4
(278)

79
(2607)
57
(1881)
21
(693)
14
(462)

86
(1204)
48
(672)
36
(504)
6
(84)

74
(2286)
40
(1236)
30
(927)
6
(185)

90
(1890)
26↓
(546)
62↑
(1302)

95
(2147)
14↓
(300)
70↑
(1502)

NK

NK

28.5↑
(2240↑)
12.3
(275)

25
(1737)
3↓
(52.0↓)

5↓
(165↓)
20
(33↓)

2↓
(28↓)
5↓
(1.4↓)

12
(370)
1.6↓
(5.9↓)

4↓
(84↓)

0↓
(0)

NK

NK

0↓
(0)

2.9↓
(50.3↓)

0↓
(0)

10
(2.8↓)

12.5
(46.2)

NK

NK

NK
NK
NK
NK

NK
NK
NK
ITPKB
c.146_147insA
NK

PIK3R1
c.1425+1G>T
de novo

LPD, lymphoproliferative disorders; IGIV, intravenous immunoglobulin; NK, not known. † patient died.
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Four patients developed B-cell LPD during the followup. P1 was diagnosed, at age 11 years, with
non-Hodgkin marginal zone B-cell lymphoma with a cutaneous infiltrate which was, subsequently,
treated with hematopoietic stem cell transplantation (HSCT) from a matched related donor. P2
was diagnosed at the age of 47 years with a low-grade mucosa-associated lymphoid tissue (MALT)
lymphoma associated with Helicobacter pylori infection, whose eradication induced MALT remission.
P5 received successful chemotherapy for a cervical Hodgkin lymphoma at the age of 19 years. P6
was diagnosed with a diffuse large B-cell lymphoma, invading the colonic mucosa, at the age of 17
years but he died from infectious complications, as previously reported [33]. A long-term longitudinal
evaluation of IgM levels well before the onset of LPD was available for P1 and P2, as illustrated in
Figure 1. Both patients had elevated IgM levels, ranging from 680 and 750 mg/dL in P1 and from 910
to 1060 mg/dL in P2. In both patients, no significant further increase in IgM levels was observed when
LPD was diagnosed, while a significant reduction was documented in P1 in the subsequent four years
J. Clin. Med. 2020, 9, x FOR PEER REVIEW
7 of 16
post chemotherapy (range 280–386 mg/dL).

Figure 1. Long-term serum immunoglobulin levels evaluation. A long-term evaluation documented
Figure 1.IgM
Long-term
levels evaluation.
A long-term
evaluation
elevated
levels 5 serum
and 10 immunoglobulin
years before lymphoproliferative
disorder
(LPD) in
patient P1documented
(A); and in
elevated
IgM levels
5 and
10 yearsinbefore
lymphoproliferative
disorder (LPD)
in patient
and
P2,
respectively
(B). IgG
decreased
P1 post
chemotherapy. Age-matched
reference
valuesP1in(a);
mg/dL
in P2,y)respectively
(b).IgA
IgG60–270,
decreased
P161–276;
post chemotherapy.
Age-matched
reference
in
(9–11
IgG 707–1919,
and in
IgM
(12 to 16 y) IgG
604–1909, IgA
61–301, values
and IgM
mg/dl
(9–11
y)
IgG
707–1919,
IgA
60–270,
and
IgM
61–276;
(12
to
16
y)
IgG
604–1909,
IgA
61–301,
59–297; (>18 y) IgG 737–1607, IgA 70–400, and IgM 40–230.
and IgM 59–297; (>18 y) IgG 737–1607, IgA 70–400, and IgM 40–230.

In both P5 and P6, elevated IgM levels were documented in the first years of life on the occasion
of an In
immunological
required
for recurrent
bacterial infections
and persisted
at the
both P5 and evaluation
P6, elevated
IgM levels
were documented
in the first
years of high
life on
the
time
of LPD
onset.
An additional
patient with
a clinical
phenotype
characterized
by elevated
IgM,
occasion
of an
immunological
evaluation
required
for recurrent
bacterial
infections
and persisted
hypogammaglobulinemia,
autoimmune
manifestations,
and LPD
was identified
butcharacterized
not included by
in
high at the time of LPD onset.
An additional
patient with
a clinical
phenotype
the
study IgM,
sincehypogammaglobulinemia,
most of the immunologicalautoimmune
evaluations were
not performed
the identified
onset of LPD.
elevated
manifestations,
and before
LPD was
but
In
and P6, in
at the
the study
time ofsince
LPDmost
diagnosis,
revealed
lymphopenia,
notP5included
of the immunological evaluation
evaluationsalso
were
not performed
before
predominantly
involving
CD4
In of
theLPD
remaining
patients,
no significant
abnormalities
the onset of LPD.
In P5the
and
P6,population.
at the time
diagnosis,
immunological
evaluation
also
were
found
in the T-cell compartment
2). the CD4 population. In the remaining patients, no
revealed
lymphopenia,
predominantly(Table
involving
significant abnormalities were found in the T-cell compartment (Table 2).
3.2. B-Lymphocyte Profiling and CD40-CD40L Expression

3.2. B-Lymphocyte
Profiling
and CD40-CD40L
Total CD19+ B
lymphocytes
percentage Expression
was reduced in P2, P3, P5, and P6 (5%, 2%, 4%, and 0%,
respectively)
[34]. CD19+CD20-IgG+
mature B cells
absent
in all
theP5,
studied
patients.
Circulating
Total CD19+
B lymphocytes percentage
was were
reduced
in P2,
P3,
and P6
(5%, 2%,
4%, and
CD19+CD27-IgD+
B
cells
(naive
B
cells)
were
normal
or
low/normal
in
all
the
patients
investigated
0%, respectively) [34]. CD19+CD20-IgG+ mature B cells were absent in all the studied patients.
(P1–P4),
implying
a normal central
B-cell
development.
memory
cells
were
Circulating
CD19+CD27-IgD+
B cells
(naive
B cells) wereCD19+CD27+IgM+
normal or low/normal
in all Bthe
patients

investigated (P1–P4), implying a normal central B-cell development. CD19+CD27+IgM+ memory B
cells were significantly reduced in all the patients studied (range 1.6%–5% of CD19+cells) [35]. As
illustrated in Table 2, three of the four patients studied also showed a significant reduction of
CD19+CD27+IgM- switched memory B cells (0%, 2.9% and 0% of CD19+cells). Intriguingly, as
shown in Figure 2, P1 and P2, who developed LPD, showed the most significant alteration in
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significantly reduced in all the patients studied (range 1.6–5% of CD19+cells) [35]. As illustrated in
Table 2, three of the four patients studied also showed a significant reduction of CD19+CD27+IgMswitched memory B cells (0%, 2.9% and 0% of CD19+cells). Intriguingly, as shown in Figure 2,
P1 and P2, who developed LPD, showed the most significant alteration in switched memory B-cell
population.
However,
theseREVIEW
patients exhibited a normal capability to produce specific IgG antibodies.
J. Clin. Med. 2020,
9, x FOR PEER
8 of 16
Unfortunately, B-lymphocyte profiling was not available for P5 and P6.
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Figure 2. B-cell immunophenotyping. Representative flow cytometric plot showing total CD19+
Figure
B-cell immunophenotyping.
Representative
flow cytometric
plot
showing
total CD19+
cells
cells
(left2.panels),
memory (CD19+ CD27+IgM+)
and switched
memory
(CD19+
CD27+IgM-)
B-cell
Figure 2. B-cell immunophenotyping. Representative flow cytometric plot showing total CD19+ cells
populations
in patients
P1(CD19+
and P2 CD27+IgM+)
(right panels),and
expressed
as percentage
total lymphocyte.
(left panels),
memory
switched
memory of
(CD19+
CD27+IgM-) B-cell
(left panels), memory (CD19+ CD27+IgM+) and switched memory (CD19+ CD27+IgM-) B-cell
populations inpopulations
patients inP1patients
and P1
P2and
(right
panels),
expressed
as percentage
of total lymphocyte.
P2 (right
panels), expressed
as percentage
of total lymphocyte.

CD40L and CD40 expression was normal in all cases except for P3, in whom CD40L expression was
CD40L and CD40 expression was normal in all cases except for P3, in whom CD40L expression
reduced.
In particular
P3expression
CD4+
T cells
were
not able
tocases
upregulate
CD40L
after stimulation,
CD40L
and
normal
allnot
forCD40L
P3, expression
inexpression
whom after
CD40L
expression
wasCD40
reduced.
In particular was
P3 CD4+
T cells in
were
able toexcept
upregulate
differently
fromstimulation,
what
was
observed
inwhat
cells
from
a healthy
control
(0.2%
vs. (0.2%
2.7%)
3). CD40LG
differently
observed
innot
cells able
from
ato
healthy
control
vs.(Figure
2.7%)expression
was reduced.
In
particular
P3 from
CD4+
T was
cells
were
upregulate
CD40L
after
(Figure
CD40LG
gene
ruled out byin
patient.
gene
alterations
were3).ruled
out
byalterations
direct
sequencing
thissequencing
patient.
stimulation,
differently
from
what
waswere
observed
indirect
cells
from ain this
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Figure 3. CD40L expression in patient P3 unstimulated and stimulated CD4+ cells as compared with
the control.

Figure 3. CD40L expression in patient P3 unstimulated and stimulated CD4+ cells as compared with
the control.
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As shown in Table 3, IgG specific antibodies were detectable in four patients including two
hypogammaglobulinemic patients before the start of replacement therapy (P1 and P4), indicating a
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already on IGIV at the time of the present study. CSR and SHM were studied in vitro in two patients
(P1 and P2). After 12 days in culture with sCD40L+IL4, B cells were able to switch towards IgE in
Table 3. In vivo and in vitro class switch recombination (CSR).
both the patients (Table 3). In addition, in these patients a normal B-cell proliferation following the
exposure to IL4+sCD40L was also found (data not shown).
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P3
P4

In vivo CSR
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region was lower than controls (P1, 1.9% and 1.2% and P2, 2.3% versus 3.5% to 6.3% of controls),
while the nucleotide substitution pattern was normal (Figure 4).

Figure 4. somatic hypermutation (SHM) results on the VH3-23 region of IgM on CD19+CD27+ isolated
B cells. (A) Frequency of mutations on IgM+CD27+ B cells purified from controls and patients. Dots
represent results for each subject. Controls: Black dots, all 10 clones mutated and white dots, 9/10
clones mutated. Patients: P1, * and P2, #; (B) Nucleotide substitution pattern for P1 (1st evaluation), P2,
and control. The same pattern was observed in P1 in the 2nd evaluation. (C) The numbers of mutated
clones from all studied clones is shown, as well as the frequency of mutations.

white dots, 9/10 clones mutated. Patients: P1, * and P2, #; (b) Nucleotide substitution pattern for
P1 (1st evaluation), P2, and control. The same pattern was observed in P1 in the 2nd evaluation. (c)
The numbers of mutated clones from all studied clones is shown, as well as the frequency of
mutations.
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3.4. NGS
WES allowed to achieve a definitive diagnosis only in P5, who showed a de novo, already
3.4. NGS
reported, splice site mutation in PIK3R1 (c.1425+1G>T), also confirmed by direct sequencing [28,29].
WES allowed to achieve a definitive diagnosis only in P5, who showed a de novo, already reported,
Sanger sequencing of PIK3CD and PIK3R1 resulted normal in the four cases studied (P1, P2, P3,
splice site mutation in PIK3R1 (c.1425+1G>T), also confirmed by direct sequencing [28,29]. Sanger
and P4). In P3, a heterozygous unreported frameshift variant in ITPKB gene (c.146_147insA),
sequencing of PIK3CD and PIK3R1 resulted normal in the four cases studied (P1, P2, P3, and P4). In P3,
predicted to damage protein function with high confidence, was identified as a potential candidate
a heterozygous unreported frameshift variant in ITPKB gene (c.146_147insA), predicted to damage
gene (Figure 5).
protein function with high confidence, was identified as a potential candidate gene (Figure 5).

Figure 5. PIK3R1 and ITPKB variations identified through WES. (A) PIK3R1 gene structure which
encodes p85α protein. The splice site mutation in patient P6 is indicated; (B) Pedigree of the family
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Figure 6. Real-time qRT-PCR of ITPKB gene mRNA expression. Quantitative RT-PCR was performed
using two specific couples of primers. ITPKB mRNA expression was normalized on Actin mRNA
content. The error bars represent technical replicates within a single experiment. Each experiment has
been repeated three times. Statistical analysis was performed by comparison between controls and
Figure
6. Real-time
qRT-PCR
ITPKB
gene
mRNA
expression.
Quantitative RT-PCR was
affected
ITPKB
mRNA content.
* p < of
0.0004
and ns
= not
statistically
significant.
performed using two specific couples of primers. ITPKB mRNA expression was normalized on
Actin mRNA content. The error bars represent technical replicates within a single experiment. Each
experiment has been repeated three times. Statistical analysis was performed by comparison
between controls and affected ITPKB mRNA content. * p < 0.0004 and ns = not statistically
significant.

4. Discussion
We report on six patients with very high IgM levels in whom classical HIGM syndromes were
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4. Discussion
We report on six patients with very high IgM levels in whom classical HIGM syndromes were
excluded. Similar to other well-defined HIGM forms, the main clinical manifestations observed in these
patients were recurrent respiratory infections, leading to the development of chronic lung changes and
B-cell LPD. Most of the patients showed alterations of the B-cell maturation process, characterized by
reduced memory and class-switched memory B cells, suggesting an impaired germinal center function.
The defect of the CD19+CD27+IgM- switched memory subset was more pronounced in two of the
four patients who developed LPD. B-cell abnormalities are usually observed in patients affected with
CVID [36,37] and in other PIDs, including X-linked lymphoproliferative syndrome type 1 (XLP1), warts,
hypogammaglobulinemia, infections, Myelokathexis (WHIM) syndrome, or DOCK8 deficiency [38–40].
Of note, CVID patients are also prone to develop lymphomas [41]. A significant correlation between
high serum IgM levels at diagnosis and the development of either polyclonal lymphocytic infiltration
or lymphoid malignancy has been reported in CVID [42]. In our cohort, most of the patients (five out
of six) showed signs of lymphoproliferation and four of them developed B-cell LPD. This data confirms
that, independent of the genetic basis, HIGM represents a risk factor for the development of LPD and
patients with HIGM of any kind need a close follow-up for early identification of these conditions.
CSR and SHM represent the two major maturation events required for an efficient humoral
response, and both take place simultaneously in the germinal center after CD40 activation. Most of the
genetically defined HIGM syndromes are due to alterations in genes involved in these processes. For
this reason, we investigated the CSR and SHM of IgM on CD19+CD27+ B cells. Intriguingly, differently
from classical HIGM syndromes, four patients showed protective antibody levels against different
antigens, suggesting a normal in vivo CSR. In two patients, CSR was also studied in vitro and resulted
normal. In the same patients, normal CSR was associated with a reduced frequency of SHM. It should
be noted that the reliability of the test in these two patients could be affected by the low numbers of
studied clones (due to the technique used and the decreased number of CD27+ cells), although it
was confirmed twice in P1, supporting the hypothesis of a defective SHM process. It should also be
noted that two patients developed chronic lung changes even in the presence of protective antibodies
titers against different antigens, suggesting that the immunological memory can be a secondary lost
in these patients or that the existing antibodies are not functioning properly. For this reason, IGIV
should be timely started in these conditions even in the presence of residual protective antibody titers,
in order to avoid the development of chronic lung changes. The impairment of SHM observed in these
patients suggests alterations of germinal center functionality, as also suggested by the reduction of
memory and class-switched memory B cells. Unfortunately, because of chemotherapy, HSCT, or death,
we were not able to test more patients for SHM. However, we cannot exclude that alterations of the
humoral immunity observed in these patients are due to a T-cell defect, even if four out of six patients
had no obvious abnormalities of the T-cell phenotype. Decreased B-cell count, especially involving
memory B cells, could also suggest a defect in B-cell proliferation or survival. The development of
B-cell tumors in these patients suggests the presence of an intrinsic B-cell defect, likely associated
with a DNA repair defect. DNA repair defects, as non-homologous end joining (NHEJ) defects or
ataxia telangiectasia (A-T) [43] and Nijmegen breakage syndromes (NBS) [44], are characterized by
defective in vitro CSR and normal frequency and pattern of SHM and are usually associated with a
HIGM phenotype. Defects in base excision or mismatch repair mechanisms affect in vitro CSR, while
SHM is usually normal in these conditions. In UNG- and MSH6-deficiencies [45,46] CSR alteration is
associated with impaired SHM, with a dramatically abnormal pattern of nucleotide substitution.
The genetic evaluation through WES achieved a definitive diagnosis in one case who showed
an already described mutation in PIK3R1. Recently, heterozygous gain-of-function mutations in
PIK3R1, encoding for p85α, one of the catalytic subunits of the PI3 kinase molecules, were reported as
responsible for a novel form of immunodeficiency [28–30]. This novel immunodeficiency, similar to
activated PI3 kinase delta syndrome (APDS) due to mutations of another subunit of the PI3K pathway,
p110δ, is characterized by elevated IgM and low IgG serum levels, recurrent respiratory infections,
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lymph node enlargement, poor growth, and elevated risk to develop lymphomas. In a second patient,
a variant of unknown significance (VUS) was identified in a potential novel candidate gene. The ITPKB
gene variant has never been reported previously, even though a deletion involving this gene has been
recently associated with a CVID phenotype with mood disorders [47]. Similar to the CVID patient
described by Luis et al., our patient showed psychiatric symptoms and lymphopenia associated with
recurrent otitis, without any infectious or eczematous skin lesions and recurrent sepsis. In our patient,
quantitative RT-PCR documented a reduction of the RNA expression as compared with controls,
suggesting that the variant identified affects the expression of the gene. Unfortunately, it was not
possible to obtain a formal demonstration of the role of the VUS identified, since the patient did not
consent to the execution of further investigations. The heterozygous status of the VUS made it difficult
to model the variant in vitro. Recent evidence in murine models documents the role of this gene in Tand B-cell development, function, and survival [48,49]. Future studies on mouse models would help to
clarify the pathogenic role of this VUS.
5. Conclusions
Taken together, our findings suggest that elevated polyclonal IgM levels, even in presence of
a normal CSR recombination, is a warning sign for a B-cell disorder and should prompt clinicians
to consider the risk of LPD in the investigation of patients affected. These patients can develop
chronic lung changes even in the presence of residual protective antibody levels, suggesting that
IGIV should be promptly started to avoid the development of complications. Moreover, an in-depth
characterization of such patients at the molecular and functional level could lead to the identification
of novel immunological pathways, paving the way to targeted therapy.
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